Carbidopa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Carbidopa. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Dyskinesia | 16.5% |
| Nausea | 5.7% |
| Hallucinations | 3.9% |
| Confusion | 3.7% |
| Dizziness | 2.9% |
| Urinary tract infection | 2.3% |
| Depression | 2.2% |
| Headache | 2% |
| Vomiting | 1.9% |
| Dream abnormalities | 1.8% |
| Dystonia | 1.8% |
| Upper respiratory infection | 1.8% |
| Dyspnea | 1.6% |
| “on-off” phenomena | 1.6% |
| Back pain | 1.6% |
| Constipation | 1.5% |
| Dry mouth | 1.4% |
| Anorexia | 1.2% |
| Diarrhea | 1.2% |
| Insomnia | 1.2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Carbidopa and levodopa extended release tablets are indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.
Source: FDA labeling via NIH DailyMed (set abff005f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.